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Summary. Disorders of amino acid metabolism or transport are most clearly 
expressed in urine. Nevertheless the interpretation of abnormalities in urinary 
amino acid excretion remains difficult. An increase or decrease of almost every 
amino acid in urine can be due to various etiology. To differentiate between 
primary and secondary aminoacido-pathies sy tematic laboratory investigation 
is necessary. Early diagnosis of disorders of amino acid metabolism or transport 
is very important, because most of them can be treated, leading to the prevention 
of (further) clinical abnormalities. In those disorders, which cannot be treated, 
early diagnosis in an index-patient may prevent he birth of other siblings by 
means of genetic ounseling and prenatal diagnosis. 
Primary aminoacidopathies can be due to genetically determined transport 
disorders and enzyme deficiencies in amino acid metabolism or degradation. 
Secondary aminoacidopathies are the result of abnormal or deficient nutrition, 
intestinal dysfunction, organ pathology or other metabolic diseases like organic 
acidurias. 
A survey of amino acid metabolism and transport abnormalities will be 
given, illustrated with metabolic pathways and characteristic abnormal amino 
acid chromatograms. 
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Introduction 
Like other inborn errors of metabolism the disorders of amino acid metabolism 
are caused by a single enzyme deficiency or a transport abnormality. The clinical 
expression of amino acid metabolism or transport disorders has a great variety. 
The course of the disease can be acute, chronic or intermittent, but the clinical 
symptoms can even be masked by multifactorial medical problems. 
Fig. 1 schematically shows the physiology of amino acids. Amino acids 
need to be transported over the intestinal wall, the cell and cell-organelle 
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membranes, the blood-brain barrier, the renal tubular wall, etc. For some 
amino acids there are special active transport mechanisms. A number of amino 
acids are sharing the same special transport mechanism (e.g. proline, hydroxy- 
proline and glycine, or cystine, ornithine, lysine and arginine). Other amino acids 
are in competition for their transport (e.g. the branched-chain amino acids, 
phenylalanine, tyrosine and tryptophan). Insuline stimulates cellular uptake of 
amino acids, except ryptophan, which is mainly bound to albumin. 
Normally there is an equilibrium between synthesis and degradation of 
proteins with respectively, consumption and liberation of amino acids. Amino 
acids can be metabolized into other amino acids, hormones, neurotransmitters, 
pigments, etc. The excess of amino acids can be degraded, mostly into organic 
acids. The first degradation step is usually the removal of nitrogen by trans- 
amination or deamination. 
Protein and amino acid metabolism is under hormonal regulation and 
depends on the nutritional state. In the anabolic state, amino acid metabolism 
and protein synthesis are enhanced, whereas in the catabolic state, amino acid 
and protein degradation dominates. 
Some enzymes involved in amino acid metabolism or degradation need 
coenzymes or cofactors, which means that vitamins, trace elements, etc. may 
play an important role in the enzymatic action. 
All amino acid metabolism or transport disorders are expressed in urine by 
accumulation of one or more amino acids, sometimes in combination with a 
decrease inthe urinary excretion of one or more other amino acids. The interpre- 
tation of the amino acid chromatogram is not always that simple. Often, addi- 
tional laboratory investigations are necessary; at least amino acid analysis 
in plasma, and in rare cases also in cerebrospinal fluid, has to be performed. 
Also other chromatographic techniques need to be used, e.g. gas chromatogra- 
phy (+ mass spectrometry) of organic acids, thin-layer chromatography of im- 
idazoles, indoles and sugars. The estimation of single metabolites a NH3, orotic 
acid, methylmalonic a id, oxalic acid, etc. might be necessary. For prenatal 
diagnosis, amino acid analysis in amniotic fluid can be a solution. To confirm 
a diagnosis, enzyme analysis in tissue (e.g. liver), blood cells, or cultured skin 
fibroblast is very often desirable or necessary. However, the most powerful new 
technique for studying human chemical genetics are those of recombinant DNA 
technology. 
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Methods 
Amino acid analysis 
Amino acid analysis was performed with an LKB 4151 Alpha Plus ® Amino Acid Analyser. 
Urines were deproteinized bymixing 500 #1 of urine with 500 #1 of a 5?/o sulfosalicylic acid 
solution containing 0,5 mmol/l norleucine (Nleu) as internal standard. The mixture was 
centrifuged for 2 rain at 10,000 rpm. The volume of sample loaded on the ion-exchange 
column was 40 #1 of the deproteinized supernatant. For analysis of amino acids we used the 
standard stepwise lution by five lithium-citrate buffers through a column containing 
8 #m cation-exchange resin. The amino acids were detected with ninhydrin reagent through 
a reaction coil set at 135°C. The O.D. range/gain was 1.0 for both the 440 nm and 570 nm 
absorbance. In the chromatograms shown, the 440 nm absorbance is the lower signal and 
the 570 nm absorbance the upper signal. The recorder speed was 2 mm/min. 
Organic acid analysis 
Organic acids in urine were estimated as described elsewhere [1]. 
Aminoacidopathies - Results and discussion 
For general information and a guidance for references to disorders of amino 
acid metabolism and transport we refer to a few handbooks [2-6]. Normal 
values are extensively given in Bremer et al. [2]. In the text we refer to the 
cataloque items of McKusick [7]. 
In Fig. 2 the picture of a normal chromatogram of amino acids in urine is 
given. We mostly use norleucine (NLEU) as an internal standard. Abnormal 
amino acid chromatograms can be compared with Fig. 2. 
The sequence of amino acid elution is only slightly variable for different 
amino acid analysers. For that reason we want to present and to discuss the 
results of amino acid analysis in the elution-sequence of the amino acids in the 
chromatogram. 
1. Taurine 
A primary metabolic disorder in taurine metabolism isnot described. Secondari- 
ly urinary taurine excretion can be increased in a catabolic state, during a high 
protein intake, as a result of acute liver failure, and in sulphite oxidase deficiency. 
2. Phosphoethanolamine 
In hypophosphatasia due to a deficiency of tissue-nonspecific (liver, bone, kid- 
ney) alkaline phosphatase isoenzyme (ALPL) phosphoethanolamine is 
accumulating in urine. (McKusick 14630, 24150, 24151). Besides phosphoetha- 
nolamine also pyrophosphate and pyridoxal-5'-phosphate r  accumulating. 
Hypophosphatasia c uses defective skeletal mineralization i infants and chil- 
dren, and osteomalacia in adults. In the perinatal form severe skeletal abormalit- 
ies can occur in utero leading to stillbirth. The infantile form can be associated 
28 W. Blom and J. G. M. Huijmans 
UREA GLY 
GLN 
s 1 
THR 
ASP  ASN 
AMINO ACIDS IN URINE 
NORMAL EXCRETION 
NLNU 
TYR 
NH 3 
HIS 
LYS 
1-Me-HIS 
3-Me-tt IS 
Fig. 2. Normal amino acid chromatogram of urine 
with nephrocalcinosis from hypercalcemia and might be fatal. At different ages 
the clinical expression can be very variable. 
Secondarily phosphoethanolamine excretion in urine can occur in some 
endocrine disorders, in different bone diseases, and as a result of hypertension. 
3. Aspartylglycosamine 
Aspartylglycosamine is a ninhydrin-positive metabolite, detectable in substan- 
tial amounts in aspartytglycosaminuria dueto lysosomal aspartylglycosamini- 
dase deficiency. (McKusick 20840) (see Fig. 3). The clinical phenotype of patients 
with aspartylglycosaminuria resemble that of mild mucopolysaccharidosis w th 
progressive mental deterioration. The disease is mainly diagnosed in Finland. 
The laboratory diagnosis can also be made by thin-layer chromatography of 
oligosaccharides (unless the urine is desalted with ion-exchange resins before 
analysis). 
4. Aspartic acid 
Aspartic aciduria together with glutamic aciduria was described in dicarboxylic 
aminoaciduria,  renal tubular transport disorder associated with hyperpro- 
linuria. (McKusick 22273). Only two patients are reported. Aspartic acid can 
also arise from the decomposition of asparagine. 
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Fig. 3. Chromatogram of amino acids in urine from a patient with lysosomal aspartyl- 
glycosylaminase deficiency. The urine is diluted 8× 
5. 4-Hydroxyproline 
In 4-hydroxy-L-proline oxidase deficiency hydroxyproline concentration i  
plasma nd urine is increased. (McKusick 23700). Mental retardation and micro- 
scopic hematuria re clinical features, although patients have been reported 
without clinical abnormalities. 
Hydroxyprolinuria s also seen in iminoglycinuria (McKusick 24260), a 
benign inborn error of amino acid transport, affecting the renal tubular reab- 
sorptive mechanism of glycine, proline and hydroxyproline. 
Hydroxyproline xcretion in urine is increased in newborns, in chronic 
uraemia, in liver cirrhosis and in some bone diseases. 
6. Threonine and serine 
Primary disorders of threonine and serine metabolism are not described. Both 
hydroxy-amino acids can be increased in vitamine B 6 deficiency. The concentra- 
tion of threonine and serine in urine rapidly diminish by bacterial decomposition 
of a urine. Threonine can be increased in liver cirrhosis. Some infant formulas 
are leading to an increased concentration of threonine in plasma and urine. 
Urinary serine excretion can also be diminished in folic acid deficiency. 
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7. Asparagine 
Disorders in asparagine metabolism are not described. Urinary asparagine 
excretion is elevated in hyperammonemia, and in Hartnup disease. 
8. Glutamic acid 
Glutamic aciduria together with aspartic aciduria and hyperprolinuria is a 
renal tubular transport disorder already mentioned under 4. aspartic acid 
(McKusick 22273). 
Only one patient with persistent glutamic acidemia was reported in the 
literature [8]. The singl e patient showed failure to thrive, vomiting, diarrhea, 
and acidosis, which persiSted espite dietary treatment. A sibling had died at the 
age of 7 weeks with a similar clinical picture. 
Glutamic acid can secondarily be increased in urine by decomposition of 
glutamine. 
9. Glutamine 
A primary metabolic defect in glutamine metabolism isnot described. Glutamine 
is secondarily increased in all conditions with hyperammonemia together with 
alanine. See also Fig. 16. In acutely sick newborns urinary glutamine xcretion 
can be increased. 
10. Sarcosine 
In sarcosine dehydrogenase d ficiency sarcosine is strongly elevated in plasma 
and urine. (McKusick 26890). Sarcosine dehydrogenase is a mitochondrial en- 
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Fig. 4. Metabolic pathway ofsarcosine metabolism 
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zyme only expressed in liver and kidney, which activates the conversion of 
sarcosine ( = N-methylglycine) into glycine (see Fig. 4). Sarcosine dehydrogenase 
contains covalently bound FAD and dissociable folate cofactors. Electron trans- 
fer from the enzyme to the main respiratory chain is mediated by ETF (electron 
transport flavoprotein) and an ETF dehydrogenase: ETF-QO (electron trans- 
port flavoprotein-ubiquinone oxidoreductase) (see Fig. 5). 
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Fig. 5. Electron transport of mitochondrial dehydrogenase r actions to the respiratory 
chain 
The phenotype of sarcosinemia or sarcosinuria can occur on the basis of at 
least three mechanisms: 
1. A defect in the holoenzyme of sarcosine dehydrogenase (e.g. apoenzyme 
deficiency, or binding defect of folate cofactors to the apoenzyme). 
2. A mutation in the electron transport flavoprotein, that is shared by sarcosine 
dehydrogenase, dimethylglycine dehydrogenase, and other acyl-CoA dehy- 
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drogenases (e.g. ETF or ETF-QO deficiency, leading to glutaric aciduria 
type II). 
3. Severe folate deficiency. 
The clinical picture of hypersarcosinemia patients is diverse. Some patients 
have mental retardation, growth delay, vomiting, hypertension, cranial stenosis, 
syndactyly, and are hypoactive. Another group of patients has only mild mental 
retardation. A third group of patients has no mental retardation, but is vomiting 
with growth retardation, and has dyslexia nd an enlarged liver. The difference 
in clinical expression might be due to a variety of genetical mutations. 
Fig. 6 shows the amino acid chromatogram in urine from a hyper- 
sarcosinemic patient, in which folic acid dependency was discovered [9]. 
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Fig. 6. Chromatogram of amino acids in urine from a patient with sarcosine dehydrogenase 
deficiency 
11. a-Aminoadipic a id 
a-Aminoadipic acid is normally transaminated into a-ketoadipic acid, which 
is converted into glutaryl-CoA catalyzed by a-ketoadipic acid dehydrogenase 
(see Fig. 7). In 1974 Fisher et al. [10] described the first two patients with 
a-aminoadipic aciduria. (McKusick 20475). A deficiency of the enzyme a-ami- 
noadipic acid transaminase was postulated. Later in 1980 Fisher and Brown 
[11] discovered that these patients were also excreting high amounts of a- 
ketoadipic acid in their urine. In the mean time other patients were reported 
with a-ketoadipic aciduria with an enzymatically proven ~-ketoadipic acid 
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dehydrogenase d ficiency (McKusick 24513). The transamination reaction is 
reversible, which means that in ct-ketoadipic a iduria not only ~-ketoadipic a id 
will accumulate, but also e-aminoadipic acid. In our opinion all patients re- 
ported with e-aminoadipic a iduria re patients with e-ketoadipic aciduria due 
to a deficiency of c~-ketoadipic a id dehydrogenase. 
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Fig. 7. Degradation pathway oflysine in relation to OH-lysine and tryptophan breakdown 
Fig. 8 shows the amino acid chromatogram of a patient with a-aminoadipic 
aciduria. If in the same urine organic acid analysis is performed, a significant 
abnormal peak of a-ketoadipic acid can be detected (see Fig. 9). The patient 
is consequently suffering from a-ketoadipic acid dehydrogenase d ficiency. 
a-Ketoadipic acid dehydrogenase d ficiency is an inborn error of lysine, 
tryptophan and hydroxylysine metabolism, which may have no clinical signifi- 
cance. Because, besides patients with psychomotor retardation and neurological 
abnormalities, cases are described with ct-ketoadipic a iduria, but without clini- 
cal abnormalities. 
We observed mild ~-aminoadipic a iduria in patients with severe seizures. 
After normalization of the convulsive condition the excretion of ~-aminoadipic 
acid also normalized. We do not have any explanation for this phenomenon. 
34 W. Blom and J. G. M. Huijmans 
a -AAA 
AMINO A~IOS IN URINE 
PATIENT P.B.C) ~ 
BORN lg-q-~'3 
a-KETO-ADIPIC AClDURIA 
NLEU 
Fig. 8. Chromatogram of amino acids in urine from a patient with e-ketoadipic acid 
dehydrogenase deficiency 
12. Proline 
Two different ypes of inherited hyperprolinemias exist. In hyperprolinemia 
type I proline oxidase is deficient. (McKusick 23950) (see step 1 in Fig. 10). 
Besides hyperprolinuria a persistent hyperprolinemia (> 450 #mol/1, but < 2000 
#mol/1) is characteristic for the diagnosis. Within the families of hyperprolinemia 
type I, patients with different forms of ocular disease, mental retardation, and 
other neurologic manifestations have been described, but these clinical abnor- 
malities were not shared by all probands. Therefore hyperprolinemia type I is 
considered as a benign disorder. 
In hyperprolinemia type II the enzyme L-ALpyrroline-5-carboxylic a id 
dehydrogenase is deficient. (McKusick 23951). See step 5 in Fig. 10. Hyper- 
prolinemia type II can be distinguished from type I by the much higher plasma 
proline concentrations (> 2000 #mol/1), and the elevated urinary excretion of 
L-ALpyrroline-5-carboxylic acid (P5C) and L-Al-pyrroline-3-hydroxy-5 - 
carboxylic acid. Not all patients with type II hyperprolinemia have clinical 
abnormalities, but in symptomatic patients seizures and mental retardation 
predominate. Type II hyperprolinemia might also be a benign metabolic 
disorder. 
In both types of hyperprolinemia plasma proline is elevated. If the plasma 
proline concentration exceeds 800 #mol/l, which is mostly the case in hyper- 
prolinemia type II, urinary hydroxyproline and glycine concentrations are also 
elevated. Glycine and hydroxyproline share a transport carrier with proline. 
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Fig. 9. Gas chromatogram of organic acids in urine from a patient with a-ketoadipic acid 
dehydrogenase deficiency, a-Ketoadipic acid is derivatized asethoxime and methylester 
When the concentration f proline is too high in the renal filtrate, reabsorption 
of hydroxyproline and glycine are competitively inhibited, and "iminoglycin- 
uria" occurs. 
In some cases of imidodipeptiduria due to prolidase deficiency (McKusick 
26413) proline and hydroxyproline excretion in urine can be increased (besides 
many proline-containing peptides). Proline excretion ismostly elevated in new- 
born infants. 
13. Glycine 
A primary disorder of glycine metabolism has appeared in the literature as 
nonketotic hyperglycinemia (McKusick 23830, 23831 and 23833). The molecular 
defect lies in the glycine cleavage system, a multienzyme complex with four 
protein components ( ee Fig. 11). These protein components are referred to 
as the P protein, H protein, T protein and L protein. The P protein is a 
pyridoxalphosphate dependent glycine decarboxylase. The H protein is a lipoic 
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acid containing protein, functioning as an aminomethyl carrier. The result of 
the P and H protein action is the liberation of CO2. The T protein is a tetrahy- 
drofolate requiring enzyme, a flavoprotein which is reduced in the presence of 
the H protein and glycine, transferring carbon 2 of glycine to tetrahydrofolate 
and liberating NH 3. The L protein is a NAD + dependent lipoamide dehydro, 
genase, regenerating the H protein. 
In the classic phenotype of nonketotic hyperglycinemia life-threatening ill- 
ness develops in early postnatal life. Most patients exhibit listlessness, lack 
of spontaneous movement, opisthotonus, myoclonus and/or grand mal seizures, 
hiccups, and failure to thrive. Survivors develop chronic seizures and deep 
mental retardation. In the classic nonketotic hyperglycinemia defective P or 
T protein has been designated. In atypical cases a defective T protein and in a 
patient with a progessive neurodegenerative disorder a defective H protein 
have been reported. 
Characteristic for nonketotic hyperglycinemia is that glycine concentration 
is not only increased in plasma and urine, but also in other body fluids, especially 
in cerebrospinal fluid. Fig. 12 shows an amino acid chromatogram of urine 
in a case of nonketotic hyperglycinemia. 
Apart from nonketotic hyperglycinemia, ketotic hyperglycinemia was de- 
scribed in the sixties. Ketotic hyperglycinemia is an associated finding in many 
(neonatal) organic acidurias. Secondarily hyperglycinuria occurs in:
1. Propionic acidemia 
2. Methylmalonic acidemia 
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3. Isovaleric acidemia 
4. 2-Methylacetoacetic aciduria 
5. D-Glyceric aciduria 
6. Hyperprolinemia Type I and II 
6. Iminoglycinuria 
7. Infants up to 6 months of age 
8. Starvation 
9. Bacterial decomposition f hippuric acid 
10. Valproic acid therapy 
Organic acid analysis is therefore ssential in the differential diagnosis of 
hyperglycinuria. In Fig. 13 an example of a chromatogram of amino acids in 
urine from a patient with propionic acidemia is shown. Propionyl-CoA is 
normally converted into D-methylmalonyl-CoA by propionyl-CoA carboxylase 
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Fig. 12. Chromatogram of amino acids in urine from a patient with a defect in the glycine 
cleavage complex 
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Fig. 13. Chromatogram of amino acids in urine from a patient with ketotic hyperglycinemia 
due to propionyl carboxylase deficiency 
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(see Fig. 14). In propionic acidemia the mitochondrial biotine nzyme propionyl- 
CoA carboxylase is deficient. (McKusick 23200, 23205 and 25326). There are 
genetically distinct forms of propionic acidemia: an apoenzyme deficiency, and 
multiple carboxylase deficiencies (holocarboxylase synthetase d ficiency and the 
late onset biotinidase deficiency). In all types of propionic acidemia biotine 
dependency might occur. 
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Fig. 14. Metabolic pathway of propionyl-CoA and methylmalonyl-CoA degradation 
Hyperglycinuria e.g. also occurs in methylmalonic acidemia. (McKusick 
25100, 25110, 25111, 25112, and 27741). In methylmalonic a idemia the conver- 
sion of D-methylmalonyl-CoA into succinyl-CoA isimpaired, due to a deficiency 
of the apoenzymes methylmalonyl racemase or mutase, or to a defect in the 
cofactor adenosylcobalamine synthesis ( ee Fig. 14). Only in vitamin B 12 depen- 
dency the prognosis of the disease is reasonable. In Fig. 15 the gas chrom- 
atogram of organic acids in urine from a patient with a vitamin B12 unresponsive 
methylmalonic a idemia is given. Besides a huge peak of methylmalonic a id, 
many peaks of propionic acid metabolites are also present. This is typical for 
the vitamin B12 unsensitive methylmalonic a idemia. 
Glycine concentration i  plasma and urine can be decreased in folic acid 
deficiency. 
14. Alanine 
No primary disorder of alanine metabolism is described. Urinary excretion 
of alanine is elevated in all disorders of lactic acidemia, and together with 
glutamine in all hyperammonemia syndromes ( ee also Fig. 17). Bacterial con- 
tamination of a urine can lead to an increase of alanine. 
Alanine excretion in the urine is decreased in ketotic hypoglycemia and in 
disregulated patients with fatty acid/3-oxidation disorders. 
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unresponsive methylmalonic acidemia 
15. H yperammonemia syndromes 
Disorders of urea synthesis usually cause hyperammonemia. Hyperammone- 
mia can primarily arise from inborn errors in urea synthesis, or secondarily 
from inborn errors in the metabolism of ornithine, lysine, tyrosine, branched 
chain amino acid (organic acidemias), and from severe liver pathology. 
The metabolic pathway of urea synthesis shown in Fig. 16. The formation 
of carbamylphosphate from ammonia by action of mitochondrial carbamyl- 
phosphate synthetase (CPS) is the first step in urea synthesis. CPS needs N- 
acetylglutamic a id as an allosteric activator. N-acetylglutamic a id is synthe- 
sized by N-acetylglutamate synthetase (NAGS). Arginine is an activator of 
NAGS, providing a mechanism for arginine to produce a positive feedback 
on ureagenesis. Mitochondrial ornithine transcarbamylase (OTC) transfers the 
carbamyl group from carbamylphosphate to ornithine under formation of 
citrulline. Citrulline leaves the mitochondria and reacts with aspartate to form 
argininosuccinic a id, activated by cytosolic argininosuccinic a id synthetase 
(AS). Argininosuccinic acid is cleaved by cytosolic argininosuccinase (AL) in 
fumaric acid and arginine. Finally, urea and ornithine are formed from arginine 
by action of cytosolic arginase. Ornithine enters the mitochondria, nd the 
so-called urea cycle is closed. 
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Fig. 16. Metabolic pathway of urea synthesis 
Two distinct carbamylphosphate synthetases are distinguished: a mito- 
chondrial ammonia dependent carbamylphosphate synthetase (CPS I), and a 
cytosolic glutamine dependent carbamylphosphate synthetase (CPS II), not 
activated by N-acetylglutamic a id. CPS II is involved in the pyrimidine synthe- 
sis with orotic acid as an important intermediate. If carbamylphosphate ccumu- 
lates, a high excretion of orotic acid in urine can be detected. 
In the hyperammonemic state alanine, glutamine, and sometimes lysine are 
increased in plasma and urine of the affected patients (see Fig. 17). Ammonia 
induces glutamate dehydrogenase to form glutamic acid from ~-ketoglutaric 
acid, and induces glutamine synthetase to form glutamine from glutamic acid. 
Pyruvic acid is transaminated to alanine induced by glutamic acid. If ¢+-keto- 
glutaric acid is depleted, lysine accumulates by partial substrate depletion of 
lysine-o+-ketoglutarate eductase (see also Fig. 7). 
The clinical presentation of neonatal hyperammonemia is mostly dramatic. 
Within 24 to 48 hours after birth the neonate may develop: 
1. Nutritional problems as soon as protein is introduced 
2. Progressive lethargy with hypothermia 
3. Areflexia and alternately hypo- and hypertonia 
4. Encephalopathy with brain edema and seizures 
5. A sepsis-like picture, but with negative bacterial cultures and not reacting on 
antibiotic therapy 
6. Coma 
7. Sudden death 
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Fig. 17. Metabolic pathway explaining increased alanine, glutamine, and lysine production. 
1" increased; $ decreased 
Some hyperammonemia 
episodic: 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
syndromes may present later in infancy with 
Protein aversion 
Vomiting 
Failure to thrive 
Hair abnormalities (trichorrhexis nodosa) 
Agitation and irritability 
Cyclic migraine 
Hepatomegaly 
Hypo- and/or hypertonia 
Stupor, coma and/or convulsions 
For the differential diagnosis of primary hyperammonemia, seeTable 1. In 
CPS I (McKusick 23730) and NAGS (McKusick 23731) deficiency no abnormal 
excretion of urea cycle intermediates or orotic acid is observed. The only bio- 
chemical symptom of hyperammonemia can be an increase of alanine and 
glutamine xcretion. As a consequence the diagnosis can only be confirmed by 
enzyme analysis in a liver biopsy. Some cases of CPS I deficiency present with 
the urinary organic acid excretion pattern as seen in 3-hydroxy-3-methylglutaric 
aciduria. 
OTC deficiency (McKusick 31125) is an X-linked dominant inherited isease, 
which means that males are severly affected, whereas females are mildly affected 
or symptom-free. OTC deficiency can be differentiated from CPS or NAGS 
deficiency by the very high orotic acid excretion in the urine. Fig. 18 shows 
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Amino acids 
Enzyme ALA + Orotic 
deficiency GLN ORN CIT ASA ARG Acid 
CPS I + + . . . . .  
NAGS + + . . . . .  
OTC + + + . . . .  + + + 
AS ++ - +++ - $ ++ 
AL ++ - + +++ ~ + 
Arginase + $ - - + + + + + 
+ increased; - normal; +decreased 
.N 
UREA 
GILN ALA 
AMINO ACIQS IN URINE 
PATIENT M.A. O x 
BORN 8-10-'02 
ORNITHINE TRAINISCARBAMYLASE 
DEFICIENCY 
NLEU 
Fig. 18. Chromatogram ofamino acids in urine from a patient with hyperammonemia due 
to ornithine transcarbamylase deficiency 
the amino acid chromatogram of urine from a male patient with OTC deficiency. 
Note  the very high excretion of GLN,  ALA and LYS. 
In AS deficiency (McKusick 21570) citrull inemia nd citrullinuria with hypo- 
argininemia will be observed. Orot ic acid is mildly increased. Fig. 19 shows 
the amino acid excretion pattern in the urine from a treated patient with 
citrullinemia. CitruUine is already strongly elevated in the amniotic fluid from 
mothers with a fetus affected by citrullinemia [12]. 
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Fig. 19. Chromatogram ofamino acids in urine from a patient with hyperammonemia due 
to argininosuccinic a id synthetase d ficiency 
In AL deficiency (McKusick 20790) a huge excretion of argininosuccinic 
acid and two cyclic metabolites can be observed (see Fig. 20). Citrulline is 
mildly and orotic acid slightly increased. If the fetus is affected, argininosuccinic 
acid is already increased in the amniotic fluid [13]. During the chromatographic 
run the cyclic metabolites are spontaneously formed,.which explains the base- 
line shift behind the argininosuccinic acid peak. Arginosuccinic acid elutes at 
the same time as the internal standard NLEU. 
In arginase deficiency (McKusick 20780) hyperargininemia and hyperarg- 
ininuria occur. The urine may contain increased concentrations of cystine, 
ornithine and lysine. Urinary orotic acid excretion is massive. The hyperam- 
monemia might be mild. Patients with argininemia excrete monosubstituted 
guanidino compounds [14]. 
Secondary hyperammonemia c n occur in: 
1. Tyrosinemia type I 
2. Hepatitis or severe liver pathology 
3. Reye's syndrome 
4. Lysinuric Protein Intolerance Syndrome 
5. Organic acidemias 
For a long time, primary hyperammonemia could hardly be treated. Starting 
in the early eithies new possibilities became available using the concept of 
AM/NO ACIDS IN URINE 
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Fig. 20. Chromatogram of amino acids in urine from a patient with hyperammonemia due 
to arginosuccinase deficiency. The urine is diluted 5x 
alternative pathways of waste-nitrogen xcretion in urine. For a overview see 
chapter 20 in [6]. 
16. Citrulline 
The primary inborn error of citruUine metabolism is described above under 
15. hyperammonemia syndromes. Citrulline excretion in urine can secondarily 
be increased in the two other urea cycle disorders argininosuccinic aciduria 
and argininemia, in saccharopinuria, and in renal insufficiency. 
17. ~-Aminobutyric acid 
There is no primary metabolic disorder of ~-aminobutyric a id metabolism 
described. An increased urinary ~-aminobutyric a id excretion can be observed 
in general aminoaciduria. 
18. Valine 
Only one patient is described with isolated hypervalinemia due to valine 
transaminase d ficiency, in a child with vomiting, failure to thrive, and drowsi- 
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ness [15]. (McKusick 27710). See enzymatic step 1 in Fig. 23. The parents howed 
also hypervalinuria. 
Valine is also increased in maple syrup urine disease (see 23. branched 
chain amino acids). 
19. C ystine 
No disorders of cysteine or cystine metabolism are described. There are only 
transport disorders. In early-onset or infantile nephropathic cystinosis 
(McKusick 21980) free, nonprotein cystine accumulates within the lysosomes 
up to levels of 1000 x normal. A defect in the ATP-dependent lysosomal efflux 
system has been detected. Cystine storage is observed in most tissues, which 
leads to tissue damage. The diagnosis can be made by .cystine analysis in 
leukocytes or cultured fibroblasts. In patients older than 1 year of age corneal 
cystine crystals can be observed using slitlamp examination. In the second half 
year of life children with cystinosis develop a renal tubular Fanconi syndrome, 
including dehydration, acidosis, vomiting, electrolyte imbalances, hypophos- 
phatemic rickets and growth retardation. 
There is also a late-onset or adolescent nephropathic type of cystinosis 
(McKusick 21990). In this form nephropathy manifests itself early in the second 
decade of life, with proteinuria due to glomerular damage rather than tubular 
damage as seen in the early-onset form. Cystine storage in white cells is in the 
heterozygote range of the early-onset type of cystinosis. 
Another cystine transport disorder is cystinuria (McKusick 22010). Of all 
aminoacidurias, cystinuria is the most frequent one. By mass screening it was 
discovered that one in every 2,000 - 15,000 individuals uffers from cystinuria. 
Most patients with cystinuria present hemselves with urinary-tract infections 
and urolithiasis. 
There are two transport systems for cystine, one with a high affinity and 
low K,,, which is shared with the dibasic amino acids ornithine, lysine and 
arginine, and another with a low affinity and high K,,, not shared with the 
dibasic amino acids. Isolated cystinuria without dibasic amino aciduria is only 
described in one patient [16]. We discovered another case, from which the 
amino acid chromatogram in urine is shown in Fig. 21. In these patients a 
defect in the low affinity, high Kr, unshared renal transport system for cystine 
is considered. 
Classical cystinuria with dibasic aminoaciduria is heterogeneous. Three 
types of cystinuric patients can be distinguished on the basis of intestinal biopsy 
investigations. In type I, there is no accumulation of cystine and the dibasic 
amino acids against agradient. On an oral loading test with cystine, no increase 
in cystine can be detected in plasma. In type II, cystine accumulates activily, but 
the dibasic amino acids do not. The oral cystine loading test has the same result 
as in type I. In type III, cystine and the dibasic amino acids accumulate, but in 
a diminished fashion. A cystine tolerance test will be normal. Heterozygotes for 
type II and III can be detected by an increased excretion of mainly cystine and 
lysine. 
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Fig. 21. Chromatogram of amino acids in urine from a patient with an isolated cystine 
transport defect 
Fig. 22 shows the amino acid chromatogram of urine from a patient with 
classical cystinuria. Cystine and the dibasic amino acids ornithine, lysine and 
arginine are largely increased. In this patient the mixed disulfide cysteinyl- 
homocysteine is clearly detectable. 
Cystine excretion is also mildly increased in homocystinuria due to a 
remethylation defect (see Fig. 33), and in aminoacidopathies affecting the dibasic 
amino acids. In young infants during the first months of life, and in renal diseases 
cystine and lysine excretion can be increased. 
20. Homocitrulline 
No primary disorder of homocitrulline metabolism isdescribed. Homocitrulline 
is secondarily increased in young infants up to one year of life, and in various 
hyperammonemia syndromes (see HHH-syndrome at 33. Ornithine). 
21. Methionine 
A primary disorder of methionine metabolism is hypermethioninemia due to 
methionine adenosyltransferase, by which S-adenosylmethionine biosynthesis 
is impaired. (McKusick 25085) (see Fig. 31). On the basis of enzyme studies 
it was concluded, that in hypermethioninemia patients ahigh K,, form of hepatic 
48 W. Blom and J. G. M. Huijmans 
i 
AMINO ACIDS IN URINE 
PATIENT J .L.  C~ BORN 1-9-'8,5 
CLASSICAL CYSTINURIA 
CYS 
NLEU 
cYs cYl/ 
N 
IRN LYS 
! 
ARG 
Fig. 22. Chromatogram of amino acids in urine from a patient with a transport defect of 
cystine and the dibasic amino acids 
methionine adenosyltransferase is d ficient, whereas the low K m form is unaffect- 
ed. Besides increased methionine concentrations in plasma and urine, urinary 
elevations of methionine sulfoxide and 4-methylthio-2-oxobutyrate are detect- 
able. In one adult patient dimethylsulfide was present in his breath. 
Most patients were discovered in the neonatal period by mass screening for 
homocystinuria. Clinically, patients with a deficiency of the high g m form of 
methionine adenosyltransferase deficiency are virtually normal. 
Hypermethioninemia and -uria can secondarily occur in homocystinuria 
(cystathionine-fl-synthase deficiency), insevere generalized liver disease, in asso- 
ciation with tyrosinemia type I, and with elevated serum folate. In neonates 
a transient hypermethioninemia has been reported. In patients with a remethyl- 
ation defect of homocysteine plasma methionine can be decreased. 
Two patients have been documented with a presumed methionine malab- 
sorption syndrome (Oasthouse disease) (McKusick 25090). The patients were 
excreting high amounts of 0~-hydroxybutyric acid, causing the abnormal smell 
of the patients. The patients had diarrhea, hyperpnea, convulsions, trikingly 
white hair and blue eyes, and were mentally retarded. 
22. Cystathionine 
Cystathionine is an intermediate metabolite of homocysteine conversion into 
cysteine (see Fig. 31). Cystathioninuria occurs in 7-cystathionase d ficiency. 
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(McKusick 21950). Most of the cysthationinuria p tients (80?/0) have no abnor- 
mal clinical symptoms. A minor part of the patients (20~) have mental retarda- 
tion with a wide assortment ofother clinical abnormalities. 
Cystathionine can secondarily be increased in: premature infants, vitamin 
B 6 deficiency, thyrotoxicosis, liver cirrhosis, neuroblastoma, ganglioblastoma, 
and hepatoblastoma. 
23. Branched chain amino acids 
Following uptake by the cell, the essential branched chain amino acids valine, 
isoleucine and leucine are either incorporated into proteins or catabolized 
for energy. The first catabolic step is a transamination to the branched chain 
ketoacids by aminotransferases with mostly a-ketoglutarate as the amino-group 
acceptor (see step 1 in Fig. 23). A deficiency of valine aminotransferase was 
already mentioned under 18. valine. A single report for a French family mentions 
a disorder in leucine and isoleucine transamination [17]. A brother and sister 
presented at 2 to 3 months of age with seizures, failure to thrive, and mental 
retardation. They showed hyperleucinemia and isoleucinemia. The urinary ami- 
no acid excretion was normal. 
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Fig. 23. Metabolic pathway of the first wo steps in branched chain amino acid degradation 
The second step in branched chain amino acid degradation is a decarboxy- 
lation and CoA-esterification of the branched chain e-keto acids, by the 
branched chain ketoacid ehydrogenase complex (see step 2 in Fig. 23). The 
mitochondrial dehydrogenase complex consists of four major proteins: 
1. A decarboxylase E1 comprising two subunits e and ft. The Ere subunit 
binds thiaminepyrophosphate, cr ating the keto acid binding site for the 
release of CO2. The Ea fl subunit is thought hat it functions in the transfer 
of the acyl moiety to E2-1ipoate. 
2. An acyltransferase E 2 containing a covalently bound lipoate, catalyzing 
the transfer of the decarboxylated branched chain acyl moiety to CoA. 
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. Lipoamide dehydrogenase Ea, a flavoprotein, reoxidizing the reduced lipoate 
created by the E2 reaction. The same protein also functions with pyruvate 
dehydrogenase (PDH) and 0~-ketoglutarate dehydrogenase (KGDH) 
complexes. 
Inherited protein defects in the branched chain e-keto acid dehydrogenase 
complex lead to the metabolic disorder Maple Syrup Urine Disease (MSUD). 
There are six variants of MSUD: a classical form (neonatal to early childhood), 
an intermediate form (infant o adult), an intermittent form (childhood to adult), 
a thiamine responsive form (infant o adult), and forms with a specific deficiency 
of El fl, E2, or E 3 (all neonatal) (McKusick 24860). 
The clinical picture varies from sudden apnea, ketoacidosis, coma, and 
death during the neonatal period to poor feeding, lethargy, (intermittent) ataxia, 
failure to thrive, and recurrent ketoacidosis during infancy. If untreated patients 
survive the first weeks of life, EEG abnormalities, evere psychomotor retarda- 
tion, generalized ystonic posturing and other structural brain dysfunction are 
the rule. 
Amino acid analysis gives very high levels of leucine and high levels of 
valine, isoleucine and allo-isoleucine inplasma nd urine (see Fig. 24). In normal 
urine allo-isoleucine is not detectable, as a result of ~-keto-fl-methylvaleric acid 
accumulation the rate of keto-enol tautomerization i  this metabolite is suffi- 
cient to produce the stereoisomeer allo-isoleucine. 
AMINO ACIDS IN URINE 
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Fig. 24. Chromatogram ofamino acids in plasma from a treated patient with maple syrup 
urine disease 
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The primary diagnosis can be confirmed by gas chromatography of organic 
acids in urine. Huge peaks of e-ketoisovaleric a id, e-ketoisocaproic a id, and 
c~-keto-fl-methylvaleric ac dare detectable. 
24. Argininosuccinic acid 
The primary inborn error argininosuccinic a iduria is previously described 
under 15. hyperammonemia syndromes. Secondarily argininosuccinic acid 
might be detectable in hyperornithinemia. 
25. Tyrosine 
The metabolic pathway of tyrosine degradation is shown in Fig. 25. In a first 
reaction tyrosine is transaminated into 4-hydroxyphenylpyruvic ac d. There 
are separate tyrosine aminotransferases in cytosol and mitochondria. The next 
step is the conversion of 4-hydroxyphenylpyruvic ac dinto homogentisic a id 
by the cytosolic enzyme 4-hydroxyphenylpyruvic aciddioxygenase. In a reaction 
of homogentisic acid oxidase, maleylacetoacetic acid is formed from homo- 
gentisic acid. Maleylacetoacetic acid is isomerized into fumarylacetoacetic acid, 
which is hydrolized by action of fumarylacetoacetate hydrolase (also called 
fumarylacetoacetase). 
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Fig. 25. Metabolic pathway of tyrosine degradation 
In tyrosinemia type I (McKusick 27670) the enzyme fumarylacetoacetate 
hydrolase (FAH) is deficient. Within the same family an acute and chronic form 
52 W. Blom and J. G. M. Huijmans 
can exist. The degree of residual FAH activity may determine whether the 
disease will be acute or chronic in the affected patient. In the acute form, 
there is failure to thrive, vomiting, diarrhea and a cabbagelike odor during 
the first week of life. In most patients hepatomegaly, fever, jaundice, ascites, 
edema, bleeding episodes, melena and epitaxis are seen to a varying degree. 
Untreated patients die within six to eight months. In the chronic form of the 
disease the clinical picture is similar but milder. The patients develop chronic 
liver disease, renal tubular dysfunction (deToni-Debre-Fanconi syndrome), and 
hypophosphatemia with rickets. Death occurs usually during the first decade. 
Hepatoma is a late complication i  at least one third of the patients. Early liver 
transplantation is owadays in most patients the ultimate therapeutic solution. 
Amino acid analysis reveals tyrosinemia and methioninemia, and generalized 
amino aciduria with a prominent tyrosinuria (see Fig. 26). Organic acid analysis 
reveals tyrosyluria (4-OH-phenylpyruvic a id and 4-OH-phenyllactic a id) and 
succinylacetone and succinylacetoacetic acid. Due to FAH deficiency accumu- 
lating fumarylacetoacetic acid is reduced into succinylacetoacetic acid, which 
decarboxylates into succinylacetone (s e Fig. 25). It is important to mention that 
succinylacetoacetic acid and succinylacetone can only be detected in fresh urine, 
because of rapid decomposition of these metabolites. Tyrosyluria originates 
from a partially reduced 4-OH-phenylpyruvic a id dioxygenase. Inhibition of 
6-aminolevulinic a id dehydratase by succinylacetone results in a high urinary 
excretion of 6-aminolevulinic a id. 
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Fig. 26. Chromatogram ofamino acids in urine from a patient with tyrosinemia type I 
(fumarylacetoacetase deficiency) 
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In tyrosinemia type II (Richner-Hanhart syndrome) cytosolic tyrosine 
transaminase is deficient. (McKusick 27660). The phenotype has also been 
described as: keratosis palmaris et plantaris. Originally Richner and Hanhart 
recognized a distinctive oculocutaneous syndrome. Clinically tyrosinemia type 
II is characterized by corneal erosions and plaques, palm and sole erosions, 
and hyperkeratosis u ually occur during the first months of life, not responding 
to conventional therapy. Some patients develop mental retardation. 
The striking abnormality in amino acid analysis is the tyrosinemia nd 
tyrosinuria. In the gas chromatogram of organic acids only tyrosyluria can be 
observed, without he presence of succinylacetone and succinylacetoacetic acid. 
In tyrosinemia type III 4-hydroxyphenylpyruvic ac d dioxygenase is defi- 
cient. (McKusick 27671). For a long time it was considered that this enzyme was 
deficient in patients with tyrosinemia type I, but the enzyme activity was never 
lower than 20~ of normal. Later FAH deficiency was discovered intyrosinemia 
type I. The only patient described with tyrosinemia type III had normal FAH 
activity and no hepatic dysfunction. The clinical picture was that of mild mental 
retardation. Besides tyrosinemia and tyrosinuria, tyrosyluria was detected. 
Neonatal tyrosinemia c n secondarily occur in prematures and dysmatures, 
due to a high protein intake. Other possibilities for secondary tyrosinemia are 
galactosemia, congenital herpes infection, congenital lues, toxoplasmosis and 
NP-F ID 
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Fig. 27. Gas chromatogram of organic acids in urine from a patient with secondary ty- 
rosinemia due to a peroxisomal disorder 
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peroxisomal disorders (e.g. Zellweger syndrome) (see Fig. 27). A high excretion 
of tyrosine in the urine can be masked by antibiotics. In the amino acid 
chromatogram of urine a huge peak of an antibiotic metabolite is eluted at 
the same time as tyrosine (see Fig. 28). However the peak is broadened and 
other broad peaks with a high 440 nm signal are mostly present. 
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Fig. 28. Chromatogram ofamino acids in urine from a patient reated with antibiotics 
26. ~-Alanine 
In the sixties one single male infant has been described with a suggested efi- 
ciency of fl-alanine-~-ketoglutarate transaminase (McKusick 23740). The pa- 
tient was convulsive, fl-Alanine, B-aminoisobutyric acid and taurine were 
excreted in excess in the urine. Also v-aminobutyric acid was detectable in urine. 
More recently a patient has been reported with a large urinary excretion of 
3-hydroxypropionic acid, fl-alanine, 3-hydroxyisobutyric a id, and E-amino- 
isobutyric acid [ 18], strongly suggesting a deficiency of methylmalonic semial- 
dehyde and malonic semialdehyde dehydrogenase. The patient was discovered 
by newborn screening for hypermethioninemia. In the first year the patient had 
episodes of diarrhea nd vomiting. The psychomotor development the patient 
had episodes of diarrhea and vomiting. The psychomotor development was 
normal. 
fl-Alanine excretion in urine is secondarily increased after kidney trans- 
plantation, when the kidney is rejected, and in carnosinuria. 
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27. Phenylalanine 
Direct or indirect disorders of phenylalanine metabolism cause hyperphenyl- 
alaninemia, generally known as phenylketonuria (PKU). PKU is one of the 
most studied inborn error of metabolism. Phenylalanine, an essential amino 
acid, is normally hydroxylated to tyrosine (step 1 in Fig. 29) by the enzyme 
phenylalanine hydroxylase (PAH). Tetrahydrobiopterin (BH4) is needed as a 
cofactor to reduce molecular oxygen. Providing electrons, BH 4 is oxidized to 
quinonoid-dihydrobiopterin (qBH2). BH4 is regenerated from qBH2 by the 
enzyme dihydropteridine reductase (DHPR) (step 2 in Fig. 29). BH 4 is de 
novo synthesized from guanosine triphosphate in several enzymatic steps. 
_ _@ o 
C-  C -C-OH HO C -~ C-  C -OH 
Phenylalanine Phe-hydroxylase .~ Tyrosine 
Tet rahydrob iopter in  q -D ihydrob iopter in  
II/f 
Guanos ine  t r iphosphate  
NAD ÷ NADH + H ÷ 
Fig. 29. Metabolic pathway of phenylalanine conversion into tyrosine 
Classical hyperphenylalaninemia (PKU I) is caused by a deficiency of PAH. 
(McKusick 26160) (see Fig. 30). PAH activity is less than 2~ of normal. Besides 
phenylalanine high urinary excretion of phenylpyruvic acid, phenyllactic acid, 
phenylacetic acid, mandelic acid and phenylglyoxylic acid can be detected by 
organic acid analysis. PKU is clinically expressed in mental retardation, behav- 
ioral abnormalities, dermatological bnormalities, hypopigmentation, and im- 
paired physical growth affecting head circumference and height. The clinical 
symptoms of PKU are now of mainly historical interest, because the disease is 
prevented by neonatal screening. 
There is also a variant form namely non-PKU hyperphenylalaninemia, in 
which PAH deficiency is less severe. If the phenylalanine concentration in 
plasma is less than 0.5 mmol/1 no treatment is necessary. 
Other types of PKU are the result of an impaired synthesis of the cofactor 
BH 4. In earlier times thesetypes of PKU were called malignant PKU, because 
despite adequate treatment a progressive neurological disease developed. In 
PKU II dihydropteridine reductase (DHPR) is deficient. (McKusick 26136). 
Patients lacking DHPR are deficient in the neurotransmitters whose synthesis 
depends on the normal activitiy of DHPR-dependent tyrosine and tryptophan 
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Fig. 30. Chromatogram of amino acids in plasma from a treated patient with PKU 
hydroxylases. Treatment of these patients exists in dietary control of the 
hyperphenylalaninemia, and in restoration of neurotransmitter homeostasis by 
oral administration f L-dopa, 5-OH-tryptophan, and other agents. 
In PKU III (McKusick 26164) enzymes for de novo synthesis of BH4 are 
deficient: guanosine triphosphate-cyclohydrolase (GTP-CH) and 6-pyruvoyl- 
tetrahydropterin synthase (6-PTS). These enzymes catalyze the first two steps in 
the biosynthesis of BH 4 from guanosine triphosphate. 
In the Western world in every PKU patient, diagnosed by a neonatal 
screening test, a BH 4 loading test (2.5-10 mg/kg) is performed. If DHPR, 
GTP-CH, or 6-PTS is deficient a rapid decrease of the elevated phenylalanine 
plasma concentration is observed after the BH 4 gift. HPLC analysis of pterins 
will give further evidence for a de novo synthesis defect of BH4. 
Another phenomenon in the hyperphenylalaninemia syndromes has become 
maternal PKU. If the intrapartum aternal phenylalanine l vel exceeds 1.1 
mmol/1 fetal pathology can occur, leading to intrauterine growth delay, congeni- 
tal heart malformation, mental retardation and microcephaly. The reason for 
fetal pathology is that in the fetus the blood phenylalanine level is 1.13-2.91 
times higher than in maternal blood. As a consequence it is necessary that the 
female PKU patient has to use again a PKU diet before she is pregnant. For 
especially female PKU patients off diet this is often very difficult. 
Hyperphenylalaninemia can secondarily occur in thenewborn, if the mother 
is an untreated PKU patient, in primary or secondary tyrosinemia, nd in a 
high neonatal protein intake. 
28. fl-Aminoisobutyric acid 
Hyper-fl-aminoisobutyric aciduria is a benign disorder, present in many human 
populations (5-10~ in whites, 40-95~ in Mongolian-derived populations, but 
not in Asian Indians). (McKusick 21010). The enzyme deficient in this disorder 
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Fig. 31. Metabolic pathway of methionine and homocysteine m tabolism 
is fl-aminoisobutyrate-pyruvate tr nsaminase, fl-Aminoisobutyric a id is an end 
product of pyrimidine metabolism. Excessive tissue breakdown results in an 
activated pyrimidine degradation and as a consequence to a high urinary excre- 
tion of fl-aminoisobutyric a id. The same abnormal excretion can be observed 
in various types of neoplastic disease. 
29. Homocystine 
Homocysteine is normally remethylated for the major part to methionine, in
which process folic acid and vitamin B~z metabolism plays an important role 
(see Fig. 31). Remethylating can also occur by use of betaine as a methyl 
donor, but this is a minor metabolic reaction. Methionine has to be activated to 
S-adenosylmethionine, to become a strong methyl donor. As a consequence of 
methylation reactions, S-adenosylhomocysteine is formed, followed by hydroly- 
sis to homocysteine. Homocysteine can escape this cycle by conversion into 
cystathionine by cystathionine-#-synthase, with pyridoxalphosphate s a co- 
factor. Cysteine is formed from cystathionine by a pyridoxalphosphate de-
pending enzyme 7-cystathioninase. If not rapidly enzymatically converted, 
homocysteine dimerizes into homocystine, or is coupled to cysteine to form the 
mixed disulphide cysteinyl-homocysteine. 
In classical homocystinuria the conversion of homocysteine into 
cystathionine is impaired, due to cystathionine-#-synthase deficiency. 
(McKusick 23620). There are two types of patients, one type not vitamin B 6 
dependent, and one type which is vitamin B 6 dependent. The patients with the 
vitamin B 6 independent type, show a variety of clinical abnormalities: 
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1. Eye abnormalities (e.g. ectopia lentis, and myopia) 
2. Skeletal abnormalities (e.g. osteoporosis, coliosis, and increased length of 
long bones) 
3. Abnormalities of the central nervous ystem (e.g. mental retardation, psychi- 
atric disturbances, and seizures) 
4. Abnormalities of the vascular system (e.g. vascular occlusions, malar flush, 
and livedo reticularis) 
5. Miscellaneous abnormalities as fair, brittle hair, thin skin, myopathy, and 
reduced clotting factors 
Patients with a mild clinical picture are mostly vitamin B 6 dependent. There is 
high evidence that patients, heterozygote for cystathionine-fl-synthase deficien- 
cy, may have thromboembolic abnormalities leading to premature occlusive 
arterial disease. 
Fig. 32 shows the amino acid chromatogram of urine from a patient with 
classical homocystinuria due to cystahionine-fl-synthase deficiency. Besides 
homocystine a peak of cysteinyl-homocysteine is also detectable. 
AMINO ACIOS IN URINE 
PATIENT M.V. (~ 
BORN 7-10-'67 
HOMOCYSTINURIA 
NLEU 
HCYS 
Fig. 32. Chromatogram ofamino acids in urine from a patient with homocystinuria due 
to cystathionine-fl-synthase deficiency 
There are other causes for homocystinuria, which will be summarized: 
1. Severe vitamin B 6 deficiency 
2. Impaired activity of 5-methyltetrahydrofolate-homocysteine m thyltransfe- 
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. 
4. 
rase, due to: 
a. 5,10-Methylenetetrahydrofolate reductase deficiency (McKusick 23625) 
b. Folate deficiency 
c. Nutritional vitamin B12 deficiency 
d. Defective absorption of vitamin B12 
e. Failure to convert cobalamin to methyl- or adenosylcobalamine 
f. Failure to accumulate methylcobalamin (McKusick 23627) 
Administration of6-azauridine triacetate, or isonicotinic acid hydrazide 
Bacterial decomposition f urinary cystathionine. 
An example of the amino acid chromatogram in urine from a patient with 
homocystinuria due to 5,10-methylenetetrahydrofolate reductase deficiency is 
given in Fig. 33. It is striking that in this urine cystine and cysteinyl-h0mocysteine 
are markedly increased, whereas homocystine is hardly detectable. 
AMINO ACIDS IN URINE 
PATIENT O.T .~ 
BORN 21~,-t1-.-'§7 
N 5-10-METHYLEN E.THF 
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Fig, 33. Chromatogram of amino acids in urine from a patient with homocystinuria due 
to 5,10-methylene-THF reductase d ficiency 
30. 7-Aminobutyric acid 
There are three primary disorders of 7-aminobutyric acid metabolism, but 
these inborn errors are not expressed in7-aminobutyric a iduria, v-Aminobutyric 
acid (GABA) can be detectable in urine in fl-alanine-e-ketoglutarate trans- 
aminase deficiency (see 26. fi-alanine), and as a result of intestinal dysbacteriosis. 
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31. Tryptophan 
Tryptophan is almost otally destroyed in an amino acid analyser. To estimate 
tryptophan in body fluids HPLC methods have to be used. Tryptophan excre- 
tion in urine can be increased in Hartnup disease (McKusick 23450), and 
due to hypoalbuminemia. Urinary tryptophan excretion can be decreased ue 
to chronic diarrhea or constipation. 
32. Ethanolamine 
Although ethanolamine is not an amino acid, ethanolamine is always present 
in the amino acid chromatogram of urine. Primary ethanolaminuria (McKusick 
22715) is described in two siblings, with cardiomegaly, generalized muscular 
hypotonia, cerebral dysfunction and death at ages 10 and 17 months. In liver 
ethanolamine kinase deficiency was demonstrated. Urinary ethanolamine can 
secondarily be increased in newborns, and in liver cirrhosis. 
33. Ornithine 
Ornithine is an intermediate in the urea cycle. Ornithine transcarbamylase 
(OTC) deficiency is a primary disorder of ornithine metabolism, not leading to 
excessive aberrations in plasma or urine concentrations ( ee under 15. hyper- 
ammonemia syndromes). Ornithine does not accumulate in OTC deficiency, 
because ornithine can escape the urea cycle by 6-transamination (see Fig. 16), 
or by a decarboxylation reaction to putrescine. Catalyzed by the pyridoxal- 
phosphate requiring enzyme ornithine-6-aminotransferase (OAT), ornithine can 
be converted into glutamic-6-semialdehyde (se  step 3 in Fig. 10). Glutamic-6- 
semialdehyde can be oxidized to glutamic acid (see step 5 in Fig. 10), or cyclizes 
spontaneously to A-pyrroline-5-carboxylic acid (see step 6 in Fig. 10). 
OAT deficiency with hyperornithinemia and hyperornithinuria is found in 
patients with gyrate atrophy of the choroid and retina. (McKusick 25887). 
These patients have mostly a slowly progressive loss of vision, usually leading 
to blindness in the fourth decade of life. The first symptoms are myopia and 
decreased night vision, followed by reduced peripheral vision with constriction 
of visual fields, development of posterior subcapsular cataracts, and total 
blindness. About half of the patients described with OAT deficiency are Finnish. 
Patients with OAT deficiency have ornithinuria nd 10- to 20-fold elevations 
of ornithine in plasma, CSF, and aqueous humor. Fig. 34 shows the amino 
acid chromatogram in urine from a patient with OAT deficiency. It is seen from 
the figure that also lysine is markedly elevated, whereas cystine and arginine are 
moderately increased. In addition to an abnormal urinary amino acid excretion 
pattern, abnormal excretion of the 6-1actam of ornithine (3-amino-piperid-2- 
one), the methylester of ornithine, and 7-glutamylornithine are documented. 
As OAT is a pyridoxalphosphate d pending enzyme, some patients have 
shown biochemical improvements on vitamin B6 therapy. Clinical improve- 
ments are not striking; it might be that the progession of the disease is slower. 
Another disease, in which ornithine is involved, is the hyperornithinemia- 
hyperammonemia-homocitrullinuria (HHH) syndrome. (McKusick 23897). 
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Fig. 34. Chromatogram of amino acids in urine from a patient with ornithine-6-amino- 
transferase d ficiency 
Most patients have a histories of intermittent hyperammonemia. They refuse to 
eat and have vomiting, lethargy, or coma, when fed high-protein formulas, milk 
or meat. Growth is inadequate and there is a developmental delay with low 
normal or severe mental retardation. Some patients have an increased bleeding 
tendency. 
No enzyme deficiency has been detected. Besides hyperornithinemia, hy- 
perammonemia and homocitrullinuria the patients how mild ornithinuria, nd 
an increased urinary excretion of 3-amino-piperid-2-one, ~,-glutamylornithine, 
orotic acid, and polyamines. 
Ornithine excretion in urine is elevated in cystinuria with dibasic amino 
aciduria s described under 19. cystine. 
34. L ysine 
The metabolic pathway of lysine degradation is shown in Fig. 7. The first 
two steps are catalyzed by a bifunctional protein e-aminoadipic semialdehyde 
synthase. The protein associates two enzyme activities: lysine-e-ketoglutarate 
reductase and saccharopine dehydrogenase. In patients with (familial) hyper- 
lysinemia, a deficiency of iysine-a-ketoglutarate eductase together with a defi- 
ciency of saccharopine dehydrogenase i  measured, indicating an impairment 
of the bifunctional protein. (McKusick 23870). The clinical picture is heteroge- 
neous: some patients have severe mental retardation, others are symptom free. 
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We were involved in two siblings with hyperlysinemia. Both patients had protein 
aversion, were extremely vomiting on a normal protein diet, and were severely 
mentally retarded. On a protein restricted iet protein aversion and vomiting 
disappeared. The younger sister, diagnosed earlier than her brother, is less 
mentally retarded. Fig. 35 shows the amino acid chromatogram in urine of 
the younger sister with hyperlysinuria ( nd hyperlysinemia). In the chromato- 
gram homocitrulline and arginine are mildly elevated. 
AMINO ACIDS IN URINE 
PATIENT J.H. 
BORN 2B-B-~B 
HYPERLYSINEMIA 
NLEU 
ARO 
Fig. 35. Chromatogram of amino acids in urine from a patient with lysine-e-ketoglutarate 
reductase d ficiency due to a defect of the bifunctional protein e-amino-adipic semialdehyde 
synthase 
Hyperlysinemia and -uria is also reported in patients with saccharopinuria. 
(McKusick 26870). In these patients accharopine d hydrogenase i  more defi- 
cient than lysine-~-ketoglutarate eductase. The first reported patient was 22 
years of age, moderately retarded with EEG abnormalities, but without seizures. 
In addition to lysine and saccharopine, urinary excretion of citrulline and 
histidine was also elevated. A second patient had spastic diplegia, but somat- 
ically and mentally she was normal. 
Membrane transport of the dibasic amino acids ornithine, lysine and ar- 
ginine is abnormal in four specific diseases: 
1. Classical cystinuria (see under 19. cystinuria). 
2. Hyperdibasic aminoaciduria type I, without hyperammonemia. (McKusick 
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22269). In 13 members of a French-Canadian kindred excessive urinary lysine, 
ornithine and arginine xcretion was discovered. Endogenous renal clearance 
of the three dibasic amino acids was increased, but that of cystine was normal. 
The patients were asymptomatic. Only the proband had a mild intestinal 
malabsorption syndrome. Another reported patient was mentally retarded. 
In four generations of the family heterozygote excretion values of the dibasic 
amino acids were found. 
3. Hyperdibasic aminoaciduria type II, with hyperammonemia. (McKusick 
22270). This disorder is known as lysinuric protein intolerance (LPI). The 
patients do not have symptoms when breast-fed, but develop protein aver- 
sion, vomiting and diarrhea fter weaning. If they are forced to high protein 
intake, they may come in coma. During and after infancy they develop growth 
retardation, hepatosplenomegaly, muscle hypotonia, sparse hair, and 
osteoporosis. Most patients are mentally normal, some are moderately 
retarded. LPI is particularly frequent in Finland. The exact cause of LPI 
is unknown. In vivo and in vitro intestinal and renal studies trongly suggest 
a transport defect of dibasic amino acids, localized in the basolateral (anti- 
luminal) membrane of the epithelial cells. 
Plasma lysine, ornithine and arginine levels are low normal. In urine 
lysine excretion is strongly increased, whereas urinary ornithine and arginine 
excretion is moderately elevated. As an indication for hyperammonemia, 
alanine and glutamine can be increased in plasma and urine, but a significant 
1 
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Fig. 36. Chromatogram of amino acids in urine from a patient with lysinuric protein 
intolerance syndrome 
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orotic aciduria is more characteristic. In plasma citrulline concentration is 
elevated. Fig. 36 shows the amino acid excretion pattern in urine from a 
patient with LPI. 
4. Lysine malabsorption or isolated lysinuria. (McKusick 24795). One Japanese 
patient was described with severe mental retardation, convulsions, growth 
failure, and signs of malnutrition. Only intestinal ysine absorption was 
decreased and there was isolated lysinuria. Blood ammonia was always 
normal. 
Urinary lysine and cystine concentration can secondarily be increased in new- 
borns during the first months of life. Lysine excretion can be elevated in 
hyperammonemia syndromes. 
35. 1-Methylhistidine 
No primary disorder of 1-methylhistidine metabolism is reported. 1-Methyl- 
histidine is synthesized from histidine, and can be liberated by hydrolysis of 
anserine (see Fig. 37). Urinary 1-methylhistidine can secondarily be increased 
due to renal insufficiency, and by alimentary cause (chicken meat). 
36. Histidine 
Pathways of histidine catabolism are given in Fig. 37. The most important 
pathway of histidine degradation is through urocanic acid. A primary disorder 
of histidine metabolism is histidinemia, due to histidase deficiency, which affects 
the conversion of histidine into urocanic acid. (McKusick 23580). It is generally 
accepted now that histidinemia is a benign metabolic disorder. As a result of 
histidine accumulation other degradation reactions are activated, leading to 
secondary elevated urinary excretion of imidazolepyruvic acid, imidazolelactic 
acid, and imidazoleacetic acid. These metabolites can be detected in urine by 
thin-layer chromatography ofimidazoles, or by HPLC. Fig. 38 shows the amino 
acid chromatogram in urine from a patient with histidinemia. 
In a few patients isolated histidinuria without histidinemia is described. 
(McKusick 23583). Intestinal and renal tubular transport of histidine are im- 
paired. Mental retardation or myoclonic seizures were associated clinical 
symptoms. 
Urinary histidine excretion can secondarily be increased in newborns, and 
in folic acid deficiency. 
37. 3-Methylhistidine 
No primary defect in 3-methylhistidine metabolism is described. 3-Methyl- 
histidine is synthesized out of histidine. Secondarily 3-methylhistidine can be 
increased in urine by malnutrition, or starvation. 
38. Carnosine and anserine 
Carnosine is a dipeptide: fl-alanyl-L-histidine (see Fig. 37). In humans carnosine 
is hydrolyzed by tissue carnosinase and serum carnosinase. Patients have been 
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Fig. 37. Metabolic pathway of histidine degradation 
described with carnosinuria due to serum carnosinase deficiency. (McKusick 
21220). Patients have neurological symptoms, like myoclonic seizures, and psy- 
chomotor retardation. In young infants up to 2 years of age serum carnosinase 
activity is low. In patients with persistent carnosinuria due to serum carnosinase 
deficiency the dipeptide anserine (]~-alanine-1-methyl-histidine) is also elevated 
in urine. Anserine has an alimentary origin (chicken, special kinds of meat), and 
is normally also hydrolyzed by serum carnosinase. 
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Fig. 38. Chromatogram of amino acids in urine from a patient with histidase deficiency 
39. Arginine 
A primary disorder of arginine metabolism has been described above under 
15. hyperammonemia syndromes. Arginine transport is defective in classical 
cystinuria (see 19. cystinuria), and in dibasic aminoaciduria type I and II (see 
34. lysine). Urinary arginine xcretion is secondarily increased in ornithinemia 
(see 33. ornithine) and in hyperlysinemia (see 34. lysine). 
Conclusions 
An dedicated amino acid analyzer remains an important tool in the diagnosis of 
aminoacidopathies. Inspite of numerous attempts to use modern HPLC meth- 
ods to analyze amino acids in physiological f uids, we still belief that in the 
metabolic field, there is no alternative for the dedicated amino acid analyzer. 
Greater experience with the inborn errors of amino acid metabolism has led 
to increased evidence for genetic heterogeneity, which is confirmed by results 
of recombinant DNA technology [6]. Many disorders are now known to contain 
clinically and biochemically apparent subgroups. Genetic disorders need to be 
distinguished from acquired abnormalities. We have tried to make a contribu- 
tion to the differential diagnosis of (inherited) amino acid metabolism or trans- 
port disorders. 
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